EU/3/13/1139: Orphan designation for the treatment of amyotrophic lateral sclerosis

Sodium chlorite

Overview

On 19 June 2013, orphan designation (EU/3/13/1139) was granted by the European Commission to Shore Limited, United Kingdom, for sodium chlorite (also known as NP001) for the treatment of amyotrophic lateral sclerosis.

The sponsorship was transferred to FGK Representative Services GmbH, Germany in December 2017.

Key facts

Active substance
Sodium chlorite
Intended use
Treatment of amyotrophic lateral sclerosis
Orphan designation status
Positive
EU designation number
EU/3/13/1139
Date of designation
19/06/2013
Sponsor
FGK Representative Services GmbH
Heimeranstrasse 35
80339 Munich
Germany
Tel. +49 89 89 31 19 22
E-mail: info@fgk-rs.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
11 ratings
2 ratings
1 rating